Patient's perception of symptoms related to morning activity in chronic obstructive pulmonary disease: The SYMBOL study

Korean Journal of Internal Medicine

Volumn 27, Issue 4, 2012, Pages 426-435

  Kim, Yeon Jae ^a   Lee, Byung Ki ^a   Jung, Chi Young ^b   Jeon, Young June ^b   Hyun, Dae Sung ^c   Kim, Kyung Chan ^c   Yu, Sung Ken ^d   Choi, Hye Sook ^e   Shin, Won Hyuk ^f   Lee, Kwan Ho ^d  

^a Daegu Fatima Hospital   (South Korea)

^b Keimyung University School of Medicine   (South Korea)

^c Catholic University of Daegu   (South Korea)

^d Yeungnam University College of Medicine   (South Korea)

^e Dongguk University College of Medicine   (South Korea)

^f Handong University   (South Korea)

Author keywords

Activities; Chronic obstructive pulmonary disease; Morning; Perception; Symptoms

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; MUSCARINIC RECEPTOR BLOCKING AGENT; XANTHINE;

AGED; ARTICLE; CHEST TIGHTNESS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; COUGHING; DAILY LIFE ACTIVITY; DISEASE SEVERITY; DYSPNEA; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; MAJOR CLINICAL STUDY; MALE; MORBIDITY; OBSERVATIONAL STUDY; PATIENT ASSESSMENT; PREVALENCE; PROSPECTIVE STUDY; QUESTIONNAIRE; SLEEP DISORDER; SYMPTOMATOLOGY; WHEEZING;

ACTIVITIES; CHRONIC OBSTRUCTIVE PULMONARY DISEASE; MORNING; PERCEPTION; SYMPTOMS;

ACTIVITIES OF DAILY LIVING; AGED; CIRCADIAN RHYTHM; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; MALE; MIDDLE AGED; PERCEPTION; PROSPECTIVE STUDIES; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUESTIONNAIRES;

EID: 84871812824     PISSN: 12263303     EISSN: 20056648     Source Type: Journal    
DOI: 10.3904/kjim.2012.27.4.426     Document Type: Article

References (37)

1. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for diagnosis, management, and prevention of chronic obstructive pulmonary disease [Internet]. 2011 rev. Global Initiative for Chronic Obstructive Lung Disease, c2011 [cited 2012 Mar 25]. Available from: http://www.goldcopd.org/uploads/users/files/GOLD_Report_2011_Feb21.pdf.
2. Kim YJ, Jung CY, Shin HW, Lee BK. Biomass smoke induced bronchial anthracofibrosis: presenting features and clinical course. Respir Med 2009;103:757-765.
3. Viegi G, Scognamiglio A, Baldacci S, Pistelli F, Carrozzi L. Epidemiology of chronic obstructive pulmonary disease (COPD). Respiration 2001;68:4-19.
4. Kim DS, Kim YS, Jung KS, et al. Prevalence of chronic obstructive pulmonary disease in Korea: a population-based spirometry survey. Am J Respir Crit Care Med 2005;172:842-847.
5. Hilleman DE, Dewan N, Malesker M, Friedman M. Pharmacoeconomic evaluation of COPD. Chest 2000;118:1278-1285.
6. Miravitlles M, Murio C, Guerrero T, Gisbert R; DAFNE Study Group. Decisiones sobre Antibioticoterapia y Farmacoeconomía en la EPOC: pharmacoeconomic evaluation of acute exacerbations of chronic bronchitis and COPD. Chest 2002;121:1449-1455.
7. Masa JF, Sobradillo V, Villasante C, et al. Costs of chronic obstructive pulmonary disease in Spain: estimation from a population-based study. Arch Bronconeumol 2004;40:72-79.
8. Rutschmann OT, Janssens JP, Vermeulen B, Sarasin FP. Knowledge of guidelines for the management of COPD: a survey of primary care physicians. Respir Med 2004;98:932-937.
9. Barr RG, Celli BR, Martinez FJ, et al. Physician and patient perceptions in COPD: the COPD Resource Network Needs Assessment Survey. Am J Med 2005;118:1415.
10. Haughney J, Partridge MR, Vogelmeier C, et al. Exacerbations of COPD: quantifying the patient's perspective using discrete choice modelling. Eur Respir J 2005;26:623-629.
11. Rennard S, Decramer M, Calverley PM, et al. Impact of COPD in North America and Europe in 2000: subjects' perspective of Confronting COPD International Survey. Eur Respir J 2002;20:799-805.
12. Miravitlles M, Anzueto A, Legnani D, Forstmeier L, Fargel M. Patient's perception of exacerbations of COPD: the PERCEIVE study. Respir Med 2007;101:453-460.
13. Partridge MR, Karlsson N, Small IR. Patient insight into the impact of chronic obstructive pulmonary disease in the morning: an internet survey. Curr Med Res Opin 2009;25:2043-2048.
14. Kessler R, Partridge MR, Miravitlles M, et al. Symptom variability in patients with severe COPD: a pan-European cross-sectional study. Eur Respir J 2011;37:264-272.
15. Postma DS, Koeter GH, Mark TW, Reig RP, Sluiter HJ. The effects of oral slow-release terbutaline on the circadian variation in spirometry and arterial blood gas levels in patients with chronic airflow obstruction. Chest 1985;87:653-657.
16. Calverley PM, Lee A, Towse L, van Noord J, Witek TJ, Kelsen S. Effect of tiotropium bromide on circadian variation in airflow limitation in chronic obstructive pulmonary disease. Thorax 2003;58:855-860.
17. van Noord JA, Aumann JL, Janssens E, et al. Effects of tiotropium with and without formoterol on airflow obstruction and resting hyperinflation in patients with COPD. Chest 2006;129:509-517.
18. McCarley C, Hanneman SK, Padhye N, Smolensky MH. A pilot home study of temporal variations of symptoms in chronic obstructive lung disease. Biol Res Nurs 2007;9:8-20.
19. American Thoracic Society. Standardization of spirometry, 1994 update. Am J Respir Crit Care Med 1995;152:1107-1136.
20. Morris JF. Spirometry in the evaluation of pulmonary function. West J Med 1976;125:110-118.
21. Sensormedics. Pulmonary Utilities Operator's Manual: Predicted Normal Equations. Yorba Linda, CA: Sensormedics Co., 1988.
22. Fritzsche A, Clamor A, von Leupoldt A. Effects of medical and psychological treatment of depression in patients with COPD: a review. Respir Med 2011;105:1422-1433.
23. Monteleone P, Maj M. The circadian basis of mood disorders: recent developments and treatment implications. Eur Neuropsychopharmacol 2008;18:701-711.
24. Mahler DA, Tomlinson D, Olmstead EM, Tosteson AN, O'Connor GT. Changes in dyspnea, health status, and lung function in chronic airway disease. Am J Respir Crit Care Med 1995;151:61-65.
25. Partridge MR, Schuermann W, Beckman O, Persson T, Polanowski T. Effect on lung function and morning activities of budesonide/formoterol versus salmeterol/fluticasone in patients with COPD. Ther Adv Respir Dis 2009;3:1-11.
26. Welte T, Miravitlles M, Hernandez P, et al. Efficacy and tol erability of budesonide/formoterol added to tiotropium in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2009;180:741-750.
27. Killian KJ, Leblanc P, Martin DH, Summers E, Jones NL, Campbell EJ. Exercise capacity and ventilatory, circulatory, and symptom limitation in patients with chronic airflow limitation. Am Rev Respir Dis 1992;146:935-940.
28. Ferrer M, Alonso J, Morera J, et al. Chronic obstructive pulmonary disease stage and health-related quality of life. The Quality of Life of Chronic Obstructive Pulmonary Disease Study Group. Ann Intern Med 1997;127:1072-1079.
29. Curtis JR, Deyo RA, Hudson LD. Pulmonary rehabilitation in chronic respiratory insufficiency 7: Health-related quality of life among patients with chronic obstructive pulmonary disease. Thorax 1994;49:162-170.
30. Oga T, Nishimura K, Tsukino M, Sato S, Hajiro T, Mishima M. Longitudinal deteriorations in patient reported outcomes in patients with COPD. Respir Med 2007;101:146-153.
31. Cazzola M, MacNee W, Martinez FJ, et al. Outcomes for COPD pharmacological trials: from lung function to biomarkers. Eur Respir J 2008;31:416-469.
32. Barnes PJ, Celli BR. Systemic manifestations and comorbidities of COPD. Eur Respir J 2009;33:1165-1185.
33. Cazzola M, Bettoncelli G, Sessa E, Cricelli C, Biscione G. Prevalence of comorbidities in patients with chronic obstructive pulmonary disease. Respiration 2010;80:112-119.
34. van den Bemt L, Schermer T, Smeele I, et al. Monitoring of patients with COPD: a review of current guidelines' recommendations. Respir Med 2008;102:633-641.
35. Benzo RP, Chang CC, Farrell MH, et al. Physical activity, health status and risk of hospitalization in patients with severe chronic obstructive pulmonary disease. Respiration 2010;80:10-18.
36. Jones PW, Harding G, Berry P, Wiklund I, Chen WH, Kline Leidy N. Development and first validation of the COPD assessment test. Eur Respir J 2009;34:648-654.
37. Partridge MR, Miravitlles M, Stahl E, Karlsson N, Svensson K, Welte T. Development and validation of the capacity of daily living during the morning questionnaire and the global chest symptoms questionnaire in COPD. Eur Respir J 2010;36:96-104.